Aurobindo Pharma’s Eugia Pharma Specialities gets FDA OK for generic Pulmicort Respules
Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampule is indicated for maintenance treatment of asthma and as prophylactic therapy in children from 12 months old to 8 years.
Aurbodino Pharma’s Eugia Pharma Specialities subsidiary has received The Food and Drug Administration’s permission to manufacture and market Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampule, which is the generic of Astrazeneca’s Pulmicort Respules.
Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampule is indicated for maintenance treatment of asthma and as prophylactic therapy in children aged 12 months to 8 years old.
[Read more: Aurobindo receives FDA approval for 3 generics]
The product, which is expected to be launched in FY25, has a market value of roughly $226.4 million for the 12 months ending September 2023, per IQVIA.